Our Developed Europe business is made up of operations in Europe’s major developed countries. The Thrombosis portfolio makes up the largest proportion of regional revenue followed by the Anaesthetics portfolio. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The injectable anticoagulants category in Developed Europe recorded flat volume growth and made up 75% of the total anticoagulants (injectables and orals).
- Anaesthetics across all of Europe (Developed and Developing) grew 4,8% to EUR1,4 billion as at 30 June 2017. General anaesthetics made up 48,3% of total value, while the topical and local anaesthetics segments made up 31,2% and 20,5% of total value, respectively.
Source: June 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue– R’billion||2017||2016 (CER)*||% change|
|High Potency & Cytotoxics||1,5||1,6||(9)|
|Other Commercial Pharmaceutical Brands||0,4||0,4||36|
* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.